 Drug Therapy, Combination
"Drug Therapy, Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapy with two or more separate preparations given for a combined effect.
| Descriptor ID |
D004359
|
| MeSH Number(s) |
E02.319.310
|
| Concept/Terms |
Drug Therapy, Combination- Drug Therapy, Combination
- Combination Chemotherapy
- Drug Polytherapy
- Drug Polytherapies
- Polytherapies, Drug
- Polytherapy, Drug
- Therapy, Combination Drug
- Chemotherapy, Combination
- Chemotherapies, Combination
- Combination Chemotherapies
- Combination Drug Therapy
- Combination Drug Therapies
- Drug Therapies, Combination
- Therapies, Combination Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Therapy, Combination".
Below are MeSH descriptors whose meaning is more specific than "Drug Therapy, Combination".
This graph shows the total number of publications written about "Drug Therapy, Combination" by people in this website by year, and whether "Drug Therapy, Combination" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 0 | 1 | 1 | | 1982 | 0 | 2 | 2 | | 1985 | 0 | 2 | 2 | | 1987 | 0 | 3 | 3 | | 1989 | 0 | 2 | 2 | | 1990 | 0 | 1 | 1 | | 1991 | 1 | 4 | 5 | | 1992 | 0 | 1 | 1 | | 1993 | 0 | 4 | 4 | | 1994 | 3 | 3 | 6 | | 1995 | 0 | 3 | 3 | | 1996 | 0 | 1 | 1 | | 1997 | 1 | 5 | 6 | | 1998 | 0 | 7 | 7 | | 1999 | 0 | 9 | 9 | | 2000 | 0 | 12 | 12 | | 2001 | 1 | 6 | 7 | | 2002 | 0 | 8 | 8 | | 2003 | 1 | 10 | 11 | | 2004 | 0 | 5 | 5 | | 2005 | 1 | 10 | 11 | | 2006 | 0 | 12 | 12 | | 2007 | 0 | 12 | 12 | | 2008 | 0 | 15 | 15 | | 2009 | 1 | 12 | 13 | | 2010 | 0 | 5 | 5 | | 2011 | 0 | 8 | 8 | | 2012 | 0 | 9 | 9 | | 2013 | 0 | 9 | 9 | | 2014 | 0 | 3 | 3 | | 2015 | 1 | 6 | 7 | | 2016 | 0 | 14 | 14 | | 2017 | 0 | 4 | 4 | | 2018 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Therapy, Combination" by people in Profiles.
-
Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307.
-
Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis. 2018 05 17; 66(11):1689-1697.
-
Khan MA, Patel KB, Nooruddin M, Swanson G, Fogg L, Keshavarzian A, Brown M. Polyethylene Glycol-3350 (Miralax®)+1.9-L sports drink (Gatorade®)+2 tablets of bisacodyl results in inferior bowel preparation for colonoscopy compared with Polyethylene Glycol-Ascorbic Acid (MoviPrep®). Turk J Gastroenterol. 2018 01; 29(1):67-74.
-
Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 05; 68(5):895-903.
-
Rubin LH, Maki PM, Springer G, Benning L, Anastos K, Gustafson D, Villacres MC, Jiang X, Adimora AA, Waldrop-Valverde D, Vance DE, Bolivar H, Alden C, Martin EM, Valcour VG. Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression. Neurology. 2017 Oct 10; 89(15):1594-1603.
-
Tseng HW, Glant TT, Brown MA, Kenna TJ, Thomas GP, Pettit AR. Early anti-inflammatory intervention ameliorates axial disease in the proteoglycan-induced spondylitis mouse model of ankylosing spondylitis. BMC Musculoskelet Disord. 2017 05 30; 18(1):228.
-
Gottlieb M, Kuhns MJ. Do Inhaled Anticholinergic Agents in Addition to ß-Agonists Improve Outcomes in Acute Asthma Exacerbations? Ann Emerg Med. 2017 09; 70(3):421-422.
-
Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853.
-
Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R, Reddy KR, Tran T, Bennett M, Nahass R, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Pearlman B, Shiffman M, Hawkins T, Curry M, Jacobson I. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1.
-
Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|